Summary and References

Myasthenic crisis is an acute exacerbation of muscle weakness in myasthenia gravis leading to respiratory failure. Emergency and critical care pharmacists play a vital role through prompt recognition, airway protection, individualized pharmacotherapy, and multidisciplinary care coordination. Optimizing therapy while avoiding medications exacerbating neuromuscular weakness is imperative for favorable outcomes.

References

1. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32(3):215-226.
2. Howard JF Jr. Clinical Overview of MG. Myasthenia Gravis Foundation of America. https://myasthenia.org. Accessed July 2023.
3. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997 Dec;42(6):789-96.
4. Cohen JA, Focus on myasthenic crisis. N Engl J Med. 1997;337:510-512.
5. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012 Dec 12;12:CD002277.
6. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-425.
7. Huda S, Al-Busaidi R, Alrawahi A, et al. Myasthenic Crisis. [Updated 2022 Jul 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.